Skip to content
Storytelling Co – Lifestyle
Author:
Addex Therapeutics
Addex Spin-out Neurosterix Closes $105 Million Series B Financing
November 11, 2026
ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES
October 29, 2026
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
October 8, 2026
Addex Therapeutics Announces Executive Management Changes
October 2, 2026
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
September 28, 2026
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
September 25, 2026
Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
September 24, 2026
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
August 26, 2026
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
July 8, 2026
Addex Shareholders Approve All Resolutions at Annual General Meeting
June 30, 2026
1
2
Next Page
→